Details of Disease

General Information of Disease (ID: DIS7FWHY)

Disease Name	Respiratory syncytial virus infection
Synonyms	infections, Human respiratory syncytial virus; respiratory syncytial virus infection; Human respiratory syncytial virus infection
Disease Class	1C80: Viral encephalitis
Definition	Infection with the respiratory syncytial virus, an RNA virus of the genus Pneumovirus, in the family Paramyxoviridae, which is characterized by the formation of syncytia in tissue culture. It causes minor respiratory infection with rhinitis and cough in adults, but is capable of causing severe bronchitis and bronchopneumonia in young children.
Disease Hierarchy	DISEM33Q: Infectious disease DISZ47G8: Mononegavirales infectious disease DIS7KC5K: Viral respiratory tract infection DIS7FWHY: Respiratory syncytial virus infection
ICD Code	ICD-11 ICD-11: 1C80 ICD-9 ICD-9: 79.6 Expand ICD-9 79.6
Disease Identifiers	MONDO ID MONDO_0001577 MESH ID D018357 UMLS CUI C0035235 MedGen ID 48424 SNOMED CT ID 55735004

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 4 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Nirsevimab	DMIBFVF	Approved	Antibody	[1]
Palivizumab	DMQM9S0	Approved	Monoclonal antibody	[2]
Resp syncytial virus ig	DMH5WOO	Approved	NA	[3]
Ribavirin	DMEYLH9	Approved	Small molecular drug	[4]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 50 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Motavizumab	DMB24H7	Phase 3	Monoclonal antibody	[5]
mRNA-1345	DMAEUEE	Phase 3	Vaccine	[6]
ResVax	DM86PDS	Phase 3	Vaccine	[7]
RSV F protein vaccine	DM5FF4I	Phase 3	NA	[8]
SAR438584	DMDMAE4	Phase 3	Antibody	[9]
VAC18193	DMQ7AMI	Phase 3	Vaccine	[10]
MEDI8897	DMGVW08	Phase 2/3	NA	[11]
MK-1654	DM2YNMI	Phase 2/3	Antibody	[12]
RSV mAb	DMON66A	Phase 2/3	NA	[8]
ALN-RSV01	DMEYNQA	Phase 2	siRNA drug	[13]
ALS-8176	DM67YA1	Phase 2	NA	[14]
EDP-938	DM32UOC	Phase 2	Small molecular drug	[15]
GS-5806	DMDAHL6	Phase 2	Small molecular drug	[16]
GSK3003891A	DMMTXAO	Phase 2	NA	[17]
GSK3389245A	DMIPI5Z	Phase 2	Vaccine	[18]
GSK3844766A	DMSEJJW	Phase 2	Vaccine	[19]
GSK3888550A	DMBGRGB	Phase 2	Vaccine	[20]
JNJ-53718678	DMJ1FXL	Phase 2	Small molecular drug	[21]
MEDI-534	DMNMJWD	Phase 2	NA	[8]
MEDI-559	DME79VB	Phase 2	NA	[22]
MEDI7510	DMYWRIA	Phase 2	NA	[23]
MLN1202	DM24SOL	Phase 2	Small molecular drug	[24]
MV-012-968	DMXFE1H	Phase 2	Vaccine	[25]
MVA-BN RSV vaccine	DM5V1EF	Phase 2	Vaccine	[8]
RI-001	DMPZ18B	Phase 2	NA	[26]
RSV recombinant vaccine	DM3F438	Phase 2	NA	[8]
RSV-F	DMBZH6M	Phase 2	NA	[27]
RV521	DMSW5XJ	Phase 2	Small molecular drug	[28]
SP0125	DMI1PVK	Phase 2	Vaccine	[29]
TTP889	DMCQARM	Phase 2	Small molecular drug	[24]
VR465	DM7SC83	Phase 2	NA	[30]
JNJ-64213175	DMLO33U	Phase 1/2	Vaccine	[31]
JNJ-64400141	DMZTSDM	Phase 1/2	NA	[32]
MEDl-559	DMPIL6Y	Phase 1/2	NA	[22]
ALX-0171	DM334N0	Phase 1	NA	[33]
JNJ-61187165	DMXV91M	Phase 1	NA	[8]
JNJ-61187191	DM1ZHOV	Phase 1	NA	[8]
JNJ-64417184	DMYJCUP	Phase 1	NA	[34]
MEDI-557	DM6ADMG	Phase 1	Antibody	[35]
MEDl-557	DM0XIJV	Phase 1	NA	[36]
mRNA-1045	DMRDEPN	Phase 1	Vaccine	[37]
mRNA-1172	DMSIEE9	Phase 1	Vaccine	[38]
mRNA-1230	DM0RBQ5	Phase 1	Vaccine	[37]
mRNA-1365	DM67EXH	Phase 1	Vaccine	[39]
mRNA-1777	DMC99PF	Phase 1	Vaccine	[40]
PF-06928316	DMA4KPX	Phase 1	Vaccine	[41]
PF-07923567	DMXUVE3	Phase 1	Small molecule	[42]
Respiratory syncytial virus VLPvaccine	DMW2Y6P	Phase 1	NA	[43]
SP0274	DM4651F	Phase 1	Vaccine	[44]
VXA-RSV-f	DMW77HQ	Phase 1	NA	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 50 Drug(s)

This Disease is Treated as An Indication in 3 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
F-50077	DMAMPOV	Discontinued in Phase 2	NA	[45]
BMS-433771	DME20VP	Terminated	Small molecular drug	[24]
HNK-20	DMUFJ1I	Terminated	NA	[47]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
TMC-353121	DMDSJO8	Preclinical	Small molecular drug	[46]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 9 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ALN-RSV02	DMQ825M	Investigative	NA	[48]
Anti-RSV mab	DMYU0G4	Investigative	Monoclonal antibody	[48]
CAL-203	DM4YSSC	Investigative	NA	[48]
IPN-100	DMKXMAA	Investigative	NA	[48]
KBRV-201	DMDAQ0N	Investigative	NA	[48]
PEV-4	DM857HO	Investigative	NA	[48]
STP-902	DMT63EK	Investigative	NA	[48]
SynGEM	DM2MZJN	Investigative	NA	[48]
YH009	DM58PQG	Investigative	Antibody	[49]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 37 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
NGFR	TTEDJN4	Limited	Biomarker	[50]
TACR1	TTZPO1L	Limited	Therapeutic	[51]
DDX58	TTVB0O3	moderate	Biomarker	[52]
ATP1A1	TTWK8D0	Strong	Biomarker	[53]
BPI	TTXCSDR	Strong	Altered Expression	[54]
C5AR1	TTHXFA1	Strong	Biomarker	[55]
CCR1	TTC24WT	Strong	Biomarker	[56]
CLCA1	TT3AF4R	Strong	Biomarker	[57]
CX3CR1	TT2T98G	Strong	Biomarker	[58]
DLL4	TTV23LH	Strong	Altered Expression	[59]
FFAR2	TT0FYAN	Strong	Biomarker	[60]
ICAM1	TTA1L39	Strong	Biomarker	[61]
IFNG	TT93WF5	Strong	Biomarker	[62]
IL13	TT0GVCH	Strong	Altered Expression	[63]
IL33	TT5MD4P	Strong	Biomarker	[64]
IL5	TTPREZD	Strong	Altered Expression	[65]
IRF1	TT4TU3L	Strong	Biomarker	[66]
IRF3	TTYR7OH	Strong	Altered Expression	[67]
MAPKAPK2	TTMUG9D	Strong	Biomarker	[68]
MYD88	TTB6Q2O	Strong	Biomarker	[69]
NCL	TTK1V5Q	Strong	Biomarker	[70]
NGF	TTDN3LF	Strong	Biomarker	[71]
SFTPD	TTGLMU7	Strong	Genetic Variation	[72]
STAT6	TTWOE1T	Strong	Biomarker	[73]
TICAM1	TT2GQT6	Strong	Biomarker	[74]
TLR3	TTD24Y0	Strong	Altered Expression	[75]
TLR7	TTRJ1K4	Strong	Biomarker	[69]
TNFSF4	TTBW580	Strong	Altered Expression	[76]
TSLP	TTHMW3T	Strong	Biomarker	[77]
CDK9	TT1LVF2	Definitive	Biomarker	[52]
G3BP1	TTG0R8Z	Definitive	Altered Expression	[78]
IFNAR2	TTMQB37	Definitive	Biomarker	[79]
NLRC5	TTWZC78	Definitive	Altered Expression	[80]
OLFM4	TTK1CX7	Definitive	Biomarker	[81]
OPRD1	TT27RFC	Definitive	Genetic Variation	[82]
PTGIS	TTLXKZR	Definitive	Genetic Variation	[83]
SMYD3	TTKLJYX	Definitive	Altered Expression	[59]
------------------------------------------------------------------------------------


⏷ Show the Full List of 37 DTT(s)

This Disease Is Related to 34 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
PDE12	OTCRN5TB	Limited	Biomarker	[84]
ROBO3	OTPVG40S	moderate	Biomarker	[52]
AZU1	OTHXU264	Strong	Altered Expression	[54]
CYBC1	OTGTH90I	Strong	Genetic Variation	[85]
IFIT2	OTI4EOAR	Strong	Biomarker	[86]
ISYNA1	OT49ONSE	Strong	Altered Expression	[87]
MIP	OTEBLU3E	Strong	Biomarker	[88]
PLAAT4	OTI66SAJ	Strong	Biomarker	[89]
RBFOX3	OTL0F3D6	Strong	Altered Expression	[75]
RNASE2	OT8Z4FNE	Strong	Biomarker	[90]
SARM1	OTEP4I5O	Strong	Biomarker	[91]
SFTPA1	OT87XL1U	Strong	Genetic Variation	[72]
SFTPA2	OT6SFOMU	Strong	Genetic Variation	[72]
TAC1	OTM842YW	Strong	Biomarker	[92]
TRIM63	OTUSWA74	Strong	Biomarker	[52]
TRIM69	OTTEGTRD	Strong	Biomarker	[74]
BATF2	OT4XBZC9	Definitive	Biomarker	[93]
C4orf3	OT6TFN1O	Definitive	Biomarker	[94]
CD8A	OTDWQJXK	Definitive	Biomarker	[95]
DCP1B	OTX7PHCI	Definitive	Biomarker	[96]
IFITM1	OTECO1G8	Definitive	Altered Expression	[97]
ING2	OT6H0EWF	Definitive	Biomarker	[95]
IVNS1ABP	OTYHL4I7	Definitive	Genetic Variation	[98]
LAMP3	OTN0XL3W	Definitive	Biomarker	[99]
MARCO	OT0NW2Q0	Definitive	Altered Expression	[100]
MICB	OTS2DVDW	Definitive	Genetic Variation	[101]
MMP19	OTLSTT2B	Definitive	Altered Expression	[102]
RNF4	OTCMXQRE	Definitive	Altered Expression	[103]
RPL18	OTJCH62J	Definitive	Altered Expression	[104]
SFTPB	OTOHS07E	Definitive	Biomarker	[105]
SFTPC	OTIZJD09	Definitive	Biomarker	[106]
SIGLEC1	OTNWSQA9	Definitive	Biomarker	[107]
TRAM1	OT3I0H8E	Definitive	Biomarker	[108]
TRIM9	OTKYG33W	Definitive	Biomarker	[109]
------------------------------------------------------------------------------------


⏷ Show the Full List of 34 DOT(s)

References

1	ClinicalTrials.gov (NCT04484935) Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children. U.S. National Institutes of Health.
2	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	Ribavirin FDA Label
5	ClinicalTrials.gov (NCT00129766) Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children. U.S. National Institutes of Health.
6	ClinicalTrials.gov (NCT05127434) A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults >=60 Years of Age. U.S.National Institutes of Health.
7	The Future of Respiratory Syncytial Virus Disease Prevention and Treatment. Infect Dis Ther. 2021 Mar;10(Suppl 1):47-60.
8	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9	ClinicalTrials.gov (NCT02325791) Study to Evaluate the Efficacy and Safety of REGN2222, for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants. U.S. National Institutes of Health.
10	ClinicalTrials.gov (NCT05101486) A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years. U.S.National Institutes of Health.
11	ClinicalTrials.gov (NCT03959488) A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children. U.S. National Institutes of Health.
12	ClinicalTrials.gov (NCT04767373) Efficacy and Safety of MK-1654 in Infants (MK-1654-004). U.S. National Institutes of Health.
13	ClinicalTrials.gov (NCT00658086) Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV). U.S. National Institutes of Health.
14	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038163)
15	ClinicalTrials.gov (NCT04816721) A Study to Evaluate EDP 938 Regimens in Infants With RSV (RSVPEDs). U.S. National Institutes of Health.
16	ClinicalTrials.gov (NCT02135614) Efficacy, Pharmacokinetics, and Safety of GS-5806 in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection. U.S. National Institutes of Health.
17	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038488)
18	ClinicalTrials.gov (NCT02927873) RSV Investigational Vaccine in RSV-seropositive Infants Aged 12 to 23 Months. U.S. National Institutes of Health.
19	ClinicalTrials.gov (NCT04657198) Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study. U.S. National Institutes of Health.
20	ClinicalTrials.gov (NCT04126213) Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants. U.S. National Institutes of Health.
21	ClinicalTrials.gov (NCT04056611) Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV) (FREESIA). U.S. National Institutes of Health.
22	ClinicalTrials.gov (NCT00767416) A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety of MEDI-559 in Healthy 1 to <24 Month-Old Children. U.S. National Institutes of Health.
23	ClinicalTrials.gov (NCT02508194) A Study to Evaluate the Efficacy of MEDI7510 in Older Adults.
24	Emerging drugs for respiratory syncytial virus infection. Expert Opin Emerg Drugs. 2009 Jun;14(2):207-17.
25	ClinicalTrials.gov (NCT04690335) Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine. U.S. National Institutes of Health.
26	ClinicalTrials.gov (NCT00632463) RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness. U.S. National Institutes of Health.
27	ClinicalTrials.gov (NCT01960686) RSV F Dose-Ranging Study in Women. U.S. National Institutes of Health.
28	ClinicalTrials.gov (NCT03258502) Safety, Pharmacokinetics and Antiviral Activity of RV521 Against RSV. U.S. National Institutes of Health.
29	Clinical pipeline report, company report or official report of Sanofi
30	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035341)
31	ClinicalTrials.gov (NCT03502707) A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older. U.S. National Institutes of Health.
32	ClinicalTrials.gov (NCT03606512) A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age. U.S. National Institutes of Health.
33	ClinicalTrials.gov (NCT01875926) ALX-0171 Phase I Pharmacokinetic Study in Healthy Male Volunteers. U.S. National Institutes of Health.
34	ClinicalTrials.gov (NCT03952507) A Study to Assess the Relative Oral Bioavailability and Food Effect of Single-dose of JNJ-64417184 in Healthy Participants. U.S. National Institutes of Health.
35	ClinicalTrials.gov (NCT01562938) MEDI-557 Adult Dosing. U.S. National Institutes of Health.
36	Respiratory syncytial virus market. Nat Rev Drug Discov. 2010 Jan;9(1):15-6.
37	ClinicalTrials.gov (NCT05585632) Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age. U.S.National Institutes of Health.
38	Clinical pipeline report, company report or official report of Moderna Therapeutics.
39	ClinicalTrials.gov (NCT05743881) A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months. U.S.National Institutes of Health.
40	A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Hum Vaccin Immunother. 2021 May 4;17(5):1248-1261.
41	Clinical pipeline report, company report or official report of Pfizer.
42	Clinical pipeline report, company report or official report of Pfizer
43	Clinical pipeline report, company report or official report of Novavax.
44	Clinical pipeline report, company report or official report of Sanofi
45	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011925)
46	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027151)
47	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004587)
48	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
49	Clinical pipeline report, company report or official report of Biocytogen
50	Combined effects of chronic nicotine and acute virus exposure on neurotrophin expression in rat lung.Pediatr Pulmonol. 2009 Nov;44(11):1075-84. doi: 10.1002/ppul.21099.
51	Respiratory syncytial virus upregulates expression of the substance P receptor in rat lungs.Am J Physiol. 1999 Oct;277(4):L831-40. doi: 10.1152/ajplung.1999.277.4.L831.
52	BRD4 Couples NF-B/RelA with Airway Inflammation and the IRF-RIG-I Amplification Loop in Respiratory Syncytial Virus Infection.J Virol. 2017 Feb 28;91(6):e00007-17. doi: 10.1128/JVI.00007-17. Print 2017 Mar 15.
53	The alpha-1 subunit of the Na+,K+-ATPase (ATP1A1) is required for macropinocytic entry of respiratory syncytial virus (RSV) in human respiratory epithelial cells.PLoS Pathog. 2019 Aug 5;15(8):e1007963. doi: 10.1371/journal.ppat.1007963. eCollection 2019 Aug.
54	Airway response to respiratory syncytial virus has incidental antibacterial effects.Nat Commun. 2019 May 17;10(1):2218. doi: 10.1038/s41467-019-10222-z.
55	Respiratory Syncytial Virus Exacerbates Kidney Damages in IgA Nephropathy Mice via the C5a-C5aR1 Axis Orchestrating Th17 Cell Responses.Front Cell Infect Microbiol. 2019 May 7;9:151. doi: 10.3389/fcimb.2019.00151. eCollection 2019.
56	Respiratory syncytial virus-induced exaggeration of allergic airway disease is dependent upon CCR1-associated immune responses.Eur J Immunol. 2005 Jan;35(1):108-16. doi: 10.1002/eji.200425439.
57	Roflumilast inhibits respiratory syncytial virus infection in human differentiated bronchial epithelial cells.PLoS One. 2013 Jul 23;8(7):e69670. doi: 10.1371/journal.pone.0069670. Print 2013.
58	CX3CR1 as a respiratory syncytial virus receptor in pediatric human lung.Pediatr Res. 2020 Apr;87(5):862-867. doi: 10.1038/s41390-019-0677-0. Epub 2019 Nov 14.
59	Notch ligand Delta-like 4 induces epigenetic regulation of Treg cell differentiation and function in viral infection.Mucosal Immunol. 2018 Sep;11(5):1524-1536. doi: 10.1038/s41385-018-0052-1. Epub 2018 Jul 23.
60	Microbiota-derived acetate protects against respiratory syncytial virus infection through a GPR43-type 1 interferon response.Nat Commun. 2019 Jul 22;10(1):3273. doi: 10.1038/s41467-019-11152-6.
61	Peroxisome proliferator-activated receptor-gamma agonists inhibit respiratory syncytial virus-induced expression of intercellular adhesion molecule-1 in human lung epithelial cells. Immunology. 2007 May;121(1):71-81. doi: 10.1111/j.1365-2567.2006.02539.x.
62	Siglec-1 inhibits RSV-induced interferon gamma production by adult Tcells in contrast to newborn Tcells.Eur J Immunol. 2018 Apr;48(4):621-631. doi: 10.1002/eji.201747161. Epub 2018 Jan 18.
63	Upregulation of H3K27 Demethylase KDM6 During Respiratory Syncytial Virus Infection Enhances Proinflammatory Responses and Immunopathology.J Immunol. 2020 Jan 1;204(1):159-168. doi: 10.4049/jimmunol.1900741. Epub 2019 Nov 20.
64	Comment on review article by Kristina Johansson and Henry McSorley.Pediatr Allergy Immunol. 2020 Apr;31(3):337-338. doi: 10.1111/pai.13184. Epub 2019 Dec 30.
65	Natural helper cells are associated with the exacerbated airway inflammation seen during RSV reinfection of neonatally primed mice.Int Immunopharmacol. 2017 Apr;45:156-162. doi: 10.1016/j.intimp.2017.02.011.
66	[Transcription factors in spinal dorsal root ganglion in rats recurrently infected with respiratory syncytial virus].Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2009 Dec;34(12):1189-95.
67	Oxidative stress modulates the expression of tolllike receptor 3 during respiratory syncytial virus infection in human lung epithelial A549 cells.Mol Med Rep. 2018 Aug;18(2):1867-1877. doi: 10.3892/mmr.2018.9089. Epub 2018 May 29.
68	Broad-Spectrum Inhibition of Respiratory Virus Infection by MicroRNA Mimics Targeting p38 MAPK Signaling.Mol Ther Nucleic Acids. 2017 Jun 16;7:256-266. doi: 10.1016/j.omtn.2017.03.008. Epub 2017 Apr 6.
69	Plasmacytoid Dendritic Cells Contribute to the Production of IFN- via TLR7-MyD88-Dependent Pathway and CTL Priming during Respiratory Syncytial Virus Infection.Viruses. 2019 Aug 8;11(8):730. doi: 10.3390/v11080730.
70	TLR4 and nucleolin influence cell injury, apoptosis and inflammatory factor expression in respiratory syncytial virus-infected N2a neuronal cells.J Cell Biochem. 2019 Sep;120(9):16206-16218. doi: 10.1002/jcb.28902. Epub 2019 May 12.
71	Neutralization of nerve growth factor (NGF) inhibits the Th2 response and protects against the respiratory syncytial virus (RSV) infection.Immunol Res. 2017 Jun;65(3):721-728. doi: 10.1007/s12026-017-8909-z.
72	Pattern recognition receptors and genetic risk for rsv infection: value for clinical decision-making?.Pediatr Pulmonol. 2011 Feb;46(2):101-10. doi: 10.1002/ppul.21348. Epub 2010 Oct 20.
73	STAT6 inhibitory peptide reduces dendritic cell migration to the lymph nodes to control Th2 adaptive immunity in the mouse lung.Eur J Immunol. 2019 Jan;49(1):157-169. doi: 10.1002/eji.201847534. Epub 2018 Dec 7.
74	Neutrophil recruitment and activation are differentially dependent on MyD88/TRIF and MAVS signaling during RSV infection.Mucosal Immunol. 2019 Sep;12(5):1244-1255. doi: 10.1038/s41385-019-0190-0. Epub 2019 Jul 29.
75	Respiratory syncytial virus prolifically infects N2a neuronal cells, leading to TLR4 and nucleolin protein modulations and RSV F protein co-localization with TLR4 and nucleolin.J Biomed Sci. 2018 Feb 10;25(1):13. doi: 10.1186/s12929-018-0416-6.
76	Critical role of OX40/OX40L in ILC2-mediated activation of CD4(+)T cells during respiratory syncytial virus infection in mice.Int Immunopharmacol. 2019 Nov;76:105784. doi: 10.1016/j.intimp.2019.105784. Epub 2019 Aug 27.
77	Sex-associated TSLP-induced immune alterations following early-life RSV infection leads to enhanced allergic disease.Mucosal Immunol. 2019 Jul;12(4):969-979. doi: 10.1038/s41385-019-0171-3. Epub 2019 May 11.
78	Respiratory syncytial virus induces host RNA stress granules to facilitate viral replication.J Virol. 2010 Dec;84(23):12274-84. doi: 10.1128/JVI.00260-10. Epub 2010 Sep 15.
79	Platelets Modulate Innate Immune Response Against Human Respiratory Syncytial Virus In Vitro.Viral Immunol. 2017 Oct;30(8):576-581. doi: 10.1089/vim.2016.0161. Epub 2017 Aug 7.
80	Respiratory Syncytial Virus Infection Upregulates NLRC5 and Major Histocompatibility Complex Class I Expression through RIG-I Induction in Airway Epithelial Cells.J Virol. 2015 Aug;89(15):7636-45. doi: 10.1128/JVI.00349-15. Epub 2015 May 13.
81	Olfactomedin 4 Serves as a Marker for Disease Severity in Pediatric Respiratory Syncytial Virus (RSV) Infection.PLoS One. 2015 Jul 10;10(7):e0131927. doi: 10.1371/journal.pone.0131927. eCollection 2015.
82	Opioid receptors control viral replication in the airways.Crit Care Med. 2013 Jan;41(1):205-14. doi: 10.1097/CCM.0b013e31826767a8.
83	Functional polymorphism of the promoter region of the prostacyclin synthase gene and severity of RSV infection in hospitalized children.J Med Virol. 2008 Nov;80(11):2015-22. doi: 10.1002/jmv.21318.
84	The Role of Phosphodiesterase 12 (PDE12) as a Negative Regulator of the Innate Immune Response and the Discovery of Antiviral Inhibitors.J Biol Chem. 2015 Aug 7;290(32):19681-96. doi: 10.1074/jbc.M115.653113. Epub 2015 Jun 8.
85	Interaction between healthcare professionals and parents is a key determinant of parental distress during childhood hospitalisation for respiratory syncytial virus infection (European RSV Outcomes Study [EROS]).Acta Paediatr. 2018 May;107(5):854-860. doi: 10.1111/apa.14224. Epub 2018 Feb 12.
86	CDK9-dependent transcriptional elongation in the innate interferon-stimulated gene response to respiratory syncytial virus infection in airway epithelial cells.J Virol. 2013 Jun;87(12):7075-92. doi: 10.1128/JVI.03399-12. Epub 2013 Apr 17.
87	KLF6 and iNOS regulates apoptosis during respiratory syncytial virus infection.Cell Immunol. 2013 May-Jun;283(1-2):1-7. doi: 10.1016/j.cellimm.2013.06.002. Epub 2013 Jun 18.
88	Peripheral blood mononuclear cells from infants hospitalized because of respiratory syncytial virus infection express T helper-1 and T helper-2 cytokines and CC chemokine messenger RNA.J Infect Dis. 2002 May 15;185(10):1388-94. doi: 10.1086/340505. Epub 2002 Apr 30.
89	Respiratory syncytial virus nonstructural proteins 1 and 2: Exceptional disrupters of innate immune responses.PLoS Pathog. 2019 Oct 17;15(10):e1007984. doi: 10.1371/journal.ppat.1007984. eCollection 2019 Oct.
90	Analysis of the predicting factors of recurrent wheezing in infants.Ital J Pediatr. 2019 Jan 29;45(1):19. doi: 10.1186/s13052-019-0609-y.
91	Resveratrol inhibits the TRIF-dependent pathway by upregulating sterile alpha and armadillo motif protein, contributing to anti-inflammatory effects after respiratory syncytial virus infection.J Virol. 2014 Apr;88(8):4229-36. doi: 10.1128/JVI.03637-13. Epub 2014 Jan 29.
92	Neurotrophins and tonsillar hypertrophy in children with obstructive sleep apnea.Pediatr Res. 2007 Oct;62(4):489-94. doi: 10.1203/PDR.0b013e31814257ed.
93	Evaluation of case definitions to detect respiratory syncytial virus infection in hospitalized children below 5 years in Rural Western Kenya, 2009-2013.BMC Infect Dis. 2016 May 21;16:218. doi: 10.1186/s12879-016-1532-0.
94	A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus.Proc Natl Acad Sci U S A. 2010 May 11;107(19):8800-5. doi: 10.1073/pnas.0912186107. Epub 2010 Apr 26.
95	Mitochondrial protein p32/HAPB1/gC1qR/C1qbp is required for efficient respiratory syncytial virus production.Biochem Biophys Res Commun. 2017 Aug 5;489(4):460-465. doi: 10.1016/j.bbrc.2017.05.171. Epub 2017 May 30.
96	Decapping protein 1 phosphorylation modulates IL-8 expression during respiratory syncytial virus infection.Virology. 2015 Jul;481:199-209. doi: 10.1016/j.virol.2015.02.043. Epub 2015 Mar 19.
97	Human respiratory syncytial virus infection is inhibited by IFN-induced transmembrane proteins.J Gen Virol. 2015 Jan;96(Pt 1):170-182. doi: 10.1099/vir.0.066555-0. Epub 2014 Sep 16.
98	Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene.Nat Med. 2005 Jan;11(1):56-62. doi: 10.1038/nm1174. Epub 2004 Dec 26.
99	Diagnosis of human respiratory syncytial virus infection using reverse transcription loop-mediated isothermal amplification.J Virol Methods. 2007 Jan;139(1):78-84. doi: 10.1016/j.jviromet.2006.09.014. Epub 2006 Oct 18.
100	Determinants of host susceptibility to murine respiratory syncytial virus (RSV) disease identify a role for the innate immunity scavenger receptor MARCO gene in human infants.EBioMedicine. 2016 Sep;11:73-84. doi: 10.1016/j.ebiom.2016.08.011. Epub 2016 Aug 6.
101	The association between MICA/MICB polymorphism and respiratory syncytial virus infection in children.Int J Immunogenet. 2017 Dec;44(6):328-336. doi: 10.1111/iji.12338. Epub 2017 Sep 18.
102	Downregulation of matrix metalloproteinase?9 induced by respiratory syncytial viral infection affects the interaction between epithelial cells and fibroblasts.Mol Med Rep. 2016 Jan;13(1):167-73. doi: 10.3892/mmr.2015.4518. Epub 2015 Nov 6.
103	Respiratory syncytial virus induces NRF2 degradation through a promyelocytic leukemia protein - ring finger protein 4 dependent pathway.Free Radic Biol Med. 2017 Dec;113:494-504. doi: 10.1016/j.freeradbiomed.2017.10.380. Epub 2017 Oct 28.
104	Ribosomal protein L18 is an essential factor that promote rice stripe virus accumulation in small brown planthopper.Virus Res. 2018 Mar 2;247:15-20. doi: 10.1016/j.virusres.2018.01.011. Epub 2018 Jan 31.
105	Surfactant protein B polymorphisms are associated with severe respiratory syncytial virus infection, but not with asthma.BMC Pulm Med. 2007 May 11;7:6. doi: 10.1186/1471-2466-7-6.
106	Surfactant protein C-deficient mice are susceptible to respiratory syncytial virus infection.Am J Physiol Lung Cell Mol Physiol. 2009 Jul;297(1):L64-72. doi: 10.1152/ajplung.90640.2008. Epub 2009 Mar 20.
107	Transient Depletion of CD169(+) Cells Contributes to Impaired Early Protection and Effector CD8(+) T Cell Recruitment against Mucosal Respiratory Syncytial Virus Infection.Front Immunol. 2017 Jul 13;8:819. doi: 10.3389/fimmu.2017.00819. eCollection 2017.
108	Respiratory syncytial virus infection modulates interleukin? production in respiratory epithelial cells through a transcription factoractivator protein? signaling pathway.Mol Med Rep. 2014 Sep;10(3):1443-7. doi: 10.3892/mmr.2014.2357. Epub 2014 Jun 26.
109	Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.BMC Infect Dis. 2017 Oct 17;17(1):687. doi: 10.1186/s12879-017-2803-0.